An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives.

Among the secondary outcomes, the ORR was also higher with cabozantinib: 20% (95% CI,12.0–30.8) versus 9% (95% CI, 3.7–17.6); whereas the median between-group difference in OS did not reach statistical significance: 26.6 months (95% CI 14.6—not estimable) with cabozantinib and 21.2 months (95% CI 16.3—27.4) with sunitinib (HR: 0.80 [95% CI 0.53—1.21]). 29 Subgroup analysis of patients stratified according to the presence or absence of bone metastases revealed no differences in the ORR or in PFS. 30 Tolerance evaluations revealed that the incidence of grade ≥3 adverse events was similar between the two groups (67% for cabozantinib versus 68% for sunitinib), with these events including diarrhea, fatigue, hypertension, and palmar-plantar erythrodysesthesia.

also in 111,027 other papers